The Effects of Hospital Based Respiratory Physiotherapy an Intervention Study among COPD Patient in Al-Zawia City, Libya
Keywords:pulmonary function â€“ spirometry â€“ quality of life â€“ activities of daily living â€“ respiratory physiotherapy
Chronic obstructive pulmonary disease (COPD) is a one of the major cause of death and disability worldwide. This study aimed to compare the quality of life (QOL), Activity of Daily Living (ADL), Pulmonary Function Test (PFT) and general health symptoms pre and after hospital-based respiratory physiotherapy program among COPD patients.
Pre and post intervention study was conducted between January and July 2010. A total of 54 subjects aged between 30 to 40 years old were recruited for this study using universal sampling method from Alzawia Teaching Hospital, Libya. Data collected were socio-demographic data, QOL (before and after the intervention) using the Short Form-36 (SF-36) questionnaire, ADL using the Barthel Index and the General Health Symptoms.
The mean SF-36 score for QOL is 30.13 (SD = 8.06) and 63.46 (SD = 13.53) before and after the physiotherapy respectively (with the p <0.0001). Patientsâ€™ Activity of Daily Living mean scores are 70.18, (SD = 16.50) and mean = 88.89 (SD = 13.28) before and after program (p< 0.0001). The general medical condition mean score after respiratory physiotherapy is 3.72 as compared to 4.96 before the respiratory physiotherapy (p< 0.0001). Pulmonary Function Test shows improvement in actual/predicted FEV1 ratio in all 54 cases with mean improvement from 55.85 before to 81.67 after the pulmonary physiotherapy (with the p <0.0001).
Hospital based respiratory physiotherapy program had significantly improved QOL, pulmonary function and activities of daily living among the subjects.
Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997; 349: 1269-76.
Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997; 349: 1436-42.
Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349: 1498-504.
Colin D. Mathers, Dejan Loncar. Updated projections of global mortality and burden of disease, 2002-2030: data sources, methods and results. Evidence and Information for Policy Working Paper. Evidence and Information for Policy. World Health Organization. October 2005.
Murray CJL, Lopez AD, Mathers CD, Stein C. The Global Burden of Disease 2000 Project: global programme on evidence for health policy discussion, paper number 36. Geneva: WHO, 2001.
Buist AS, McBurnie MA, Vollmer WM, et al, on behalf of the BOLD Collaborative Research Group. International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study. Lancet 2007; 370: 741â€“50.
Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J 2006; 28: 523â€“32.
Epidemiology of Chronic Obstructive Pulmonary Disease (COPD) G. Viegi; A. Scognamiglio; S. Baldacci; F. Pistelli; L. Carrozzi Respiration; Jan/Feb 2001; 68, 1; ProQuest Health and Medical Complete pg. 4.
European Respiratory Society. European lung white book. Huddersfield, UK: European Respiratory Society Journals; 2003.
National Heart, Lung, and Blood Institute. 2004 NHLBI morbidity and mortality chartbook on cardiovascular, lung and blood diseases [Internet]. Bethesda, MD: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health [accessed 2007 Jul 26]. Available from: http://www.nhlbi.nih.gov/resources/docs/cht-book.htm.
British Thoracic Society guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee of the BTS. Thorax 1997; 52:S1-28.
Calverley P M A; Paul Walker 2003. Chronic obstructive pulmonary disease. The Lancet; Sep 27, 2003; 362, 9389; ProQuest Health and Medical Complete pg. 1053.
Karen Duvall, Gerard W. Frank, Identifying Chronic Obstructive Pulmonary Disease in Primary Care of Urban Underserved Patients: Tools, Applications, and Challenges. Guest Editorial. Journal of the National Medical Association. Vol. 102, No. 7, JULY 2010.
Pandey MR, Regmi HN, Neupane RP, Gautam A, Bhandari DP. Domestic smoke pollution and respiratory function in rural Nepal. Tokai J Exp Clin Med 1985; 10: 471-81.
Pandey MR. Prevalence of chronic bronchitis in a rural community of the hill region of Nepal. Thorax 1984; 39: 331-36.
Perez-Padilla R, Regaldo J, Vedal S, Pare P, Sansores R, Seman M. Exposure to biomass smoke and chronic airway disease in Mexican women: a case-control study. American Journal Respiratory and Critical Care Meddicine 1996; 154: 701-06.
Peter M A Calverley COPD: Early detection and intervention Chest; May 2000; 117, 5; ProQuest Health and Medical Complete pg. S365.
Fletcher C, Pcto R.The natural history of chronic airflow obstruction. BMJ 1977; 1: 1645-48.
Peto R, Speizer FE, Cochrane AL, et al. The relevance in adults of air-flow obstruction, but not of mucus hypersecretion, to mortality from chronic lung disease: results from 20 years of prospective observation. Am Rev Respir Dis 1983; 128: 491-500.
Cozio M, Ghezzo H, Hogg JC, et al. The relations between structural changes in small airways and pulmonary function tests. N Engl J Med 1978; 298: 1277-81.
Thurlbeck WM, Wright JL. Chronic airflow obstruction, 2nd edn. Hamilton: BC Dekker, 1999.
Penman RW, O'Neill RP, Begley L. The progress of chronic airway obstruction in relation to measurements of airway resistance and lung elastic recoil. Am Rev Respir Dis 1970; 101: 536-44.
Colebatch HJ, Finucane KE, Smith MM. Pulmonary conductance and elastic recoil relationships in asthma and emphysema. J Appl Physiol 1973; 34: 143-53.
Rennard SI, Anderson W, ZuWallack R, et al. Use of a long-acting inhaled beta 2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 1087-92.
Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997; 155: 1283-89.
Dahl R, Greefhorst LAPM, Nowak D, et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164; 5: 778-84.
Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115: 957-65.
Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obsrtructive pulmonary disease Eur Respir J 2002; 19: 217-24.
Vincken W, van Noord JA, Greefhorst AP, et al; Dutch/Belgian Tiotropium Study Group. Improved health outcomes in patients with COPD during 1 year's treatment with tiotropium. Eur Respir J 2002; 19: 209-16.
Calverley PMA. Inhaled corticosteroids are beneficial in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2000; 161: 341-42.
Barnes PJ. Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2000; 161: 342-44.
Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 1999; 340: 1948-53.
Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Longterm effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353: 1819-23.
Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297-303.
The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease: N Engl J Med 2000; 343: 1902-909.
Sin DD, Tu JV. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2001; 164: 580-84.
Spencer S, Calverley PMA, Burge PS, Jones PW. Health status deterioration in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2001; 163: 122-28.
Soriano JB, Vestbo J, Pride NB, Kiri V, Maden C, Maier WC. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Bur Respir J 2002; 20: 799-805.
American Thoracic Society. Pulmonary rehabilitation. American Journal of Respiratory and Critical Care Medicine 1999; 159: 1666-82.
British Thoracic Society Standards of Care Subcommittee on Pulmonary Rehabilitation. Pulmonary rehabilitation. Thorax 2001; 56: 827-34.
Goldstein RS, Gort EH, Stubbing D, Avendano MA, Guyatt GH. Randomised controlled trial of respiratory rehabilitation. Lancet 1994; 344: 1394-97.
Wijkstra PJ, Van Altena R, Kraan J, Otten V, Postma DS, Koeter GH. Quality of life in patients with chronic obstructive pulmonary disease improves after rehabilitation at home. European Respiratory Journal 1994; 7: 269-73.
Young P, Dewse M, Fergusson W, Kolbe J. Improvements in outcomes for chronic obstructive pulmonary disease (COPD) attributable to a hospital-based respiratory rehabilitation programme. Australian New Zeeland Journal Medicine 1999; 29: 59-65.
Berry MJ, Rejeski WJ, Adair NE, Zaccaro D. Exercise rehabilitation and chronic obstructive pulmonary disease stage. Am J Respir Crit Care Med 1999; 160: 1248-53.
Griffiths TL, Burr ML, Campbell IA, et al. Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial. Lancet 2000; 355: 362-68.
The COPD Guidelines Group of the Standards of Care Committee of the BTS. BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997; 52: S5-S25.
Sridhar MK. Pulmonary rehabilitation [editorial]. BMJ 1997; 314:1361-1364.
American Thoracic Society. Comprehensive outpatient management of COPD: ATS statement; standards for the diagnosis and care of patients with chronic obstructive pulmonary.Disease. American Journal of Respiratory and Critical Care Medicin1885; 152: 456-60.
Thompson WH, Nielson CP, Carvalho P, Charan NB, Crowley JJ. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. American Journal of Respiratory and Critical Care Medicine 1996; 154: 407-12.
Davies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 1999; 354: 456-60.
Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. New England Journal Medicine 1999; 340: 1941-47.
Maltais F, Ostinelli J, Bourbeau J, et al. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine 2002; 165: 698-703.
Ries AL, Bauldoff GS, Carlin BW, et al. Pulmonary rehabilitation: Joint accp/aacvpr evidence-based clinical practice guidelines. Chest 2007; 131: 4Sâ€“42S.
Lacasse Y, Martin S, Lasserson TJ, and Goldstein RS. Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease. A cochrane systematic review. Eura Medicophys 2007; 43: 475â€“485.
The COPD Guidelines Group of the Standards of Care Committee of the British Thoracic Society. The British Thoracic Society guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997; 52 (suppl 5): 1/29.
American Thoracic Society. Pulmonary rehabilitation. Am J Respir Crit Care Med 1999; 159: 1666/82.
Lacasse Y, Brosseau L, Milne S et al . Pulmonary rehabilitation for chronic obstructive pulmonary disease (Cochrane Review). In: The Cochrane Library, Issue 4, 2002. Oxford: Update Software.
Yohannes AM, Greenwood YA, Connolly MJ, 2002.Reliability of the Manchester respiratory activities of daily living questionnaire as a postal questionnaire ageing Oxford Journal. 31(5):355-8.
Martinez FJ, Foster G, Curtis JL, et al, 2006. Predictors of mortality in patients with emphysema and severe airflow obstruction. Am J Respir Crit Care Med 173:1326â€“1334
Brian W Carl MD. Pulmonary Rehabilitationâ€”A New Gold Standard 2006. Available from; http://www.touchbriefings.com/pdf/2001/carlin1.pdf 21-12-2010.
Management of acute exacerbations of COPD: A summary and appraisal of published evidence. Douglas C McCrory, Cynthia Brown, Sarah E Gelfand, Peter B Bach. Chest. Chicago: Apr 2001. Vol. 119, Iss. 4; pg. 1190, 20 pgs.
Petersen, A.M. & Pedersen, B,K. (2005). The anti-inflammatory effects of exercise. Journal of Applied Physiology. 98(4), 1154-116.
Guyatt GH, Townsend M, Pugsley SO, Keller JL, Short HD, Taylor DW 1987. Bronchodilators in chronic airflow limitation. Am Rev Respr Dis ; 135:1069-74.
Kane CJ, Lubeck DP, Knight SJ, Spitalny M, Downs TM, Grossfeld GD, Pasta DJ, Mehta SS, Carroll PR .2003. Impact of patient educational level on treatment for patients with prostate cancerUniversity of California, San Francisco, School of Medicine, 94143-1695, USA.
Kinsman R, Fernandez E, Sprocker M, Dirks J, Covino N 1983. Multidimensional analysis of the symptoms of chronic bronchitis and emphysema. J Behav Med ; 6(4):339-57.
Ries AL, RM Kaplan, TM Limberg and LM Prewitt1995. Effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease. Ann. Intern. Med ; 122: 823-32.